Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive market.
GLP-1 drugs have dramatically changed the outlook for people with obesity.
Gaetan Bally / Keystone
After missing the first wave of GLP-1 blockbusters, Roche is investing billions in a new generation of obesity treatments. With Novo Nordisk and Eli Lilly dominating the market, can the Swiss pharma giant still find a foothold?
Generated with artificial intelligence.
This content was published on
Der Schweizer Pharmakonzern erzielt positive Ergebnisse in einer Phase-II-Studie, der Aktienkurs hat seit Jahresbeginn deutlich…
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
Il colosso elvetico del pharma vuole fare concorrenza a Novo Nordisk ed Eli Lilly nel segmento della cura dell’obesità, diventato…
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference…
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around…
